SRR934816
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 16.52431011826544
- age_years
- 51
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.647
- ANGIOGENESIS+0.621
- IL6_JAK_STAT3_SIGNALING+0.564
- TNFA_SIGNALING_VIA_NFKB+0.552
- INTERFERON_GAMMA_RESPONSE+0.546
- INTERFERON_ALPHA_RESPONSE+0.529
- TGF_BETA_SIGNALING+0.503
- HYPOXIA+0.501
- ALLOGRAFT_REJECTION+0.485
- INFLAMMATORY_RESPONSE+0.485
Top 10 suppressed
- SPERMATOGENESIS-0.389
- KRAS_SIGNALING_DN-0.380
- OXIDATIVE_PHOSPHORYLATION-0.241
- PANCREAS_BETA_CELLS-0.240
- BILE_ACID_METABOLISM-0.025
- MYOGENESIS-0.006
- FATTY_ACID_METABOLISM+0.005
- WNT_BETA_CATENIN_SIGNALING+0.030
- PEROXISOME+0.051
- HEME_METABOLISM+0.052
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934829 | — | — | 0.980 |
| 2 | SRR934782 | — | — | 0.977 |
| 3 | SRR934845 | — | — | 0.976 |
| 4 | SRR934866 | — | — | 0.972 |
| 5 | SRR934750 | — | — | 0.968 |
| 6 | SRR934926 | — | — | 0.966 |
| 7 | 18D7DFBC-A1C6-4DA8-9AF1-3A6F3E2A03BE | — | — | 0.965 |
| 8 | SRR934747 | — | — | 0.961 |
| 9 | SRR934825 | — | — | 0.960 |
| 10 | SRR934952 | — | — | 0.959 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.647 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.621 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.564 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.552 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.546 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.529 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.503 | Inavolisib | — uncovered |
| HYPOXIA | 0.501 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.485 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.485 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.478 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.460 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.454 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.451 | Idelalisib | — uncovered |
| APOPTOSIS | 0.438 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.416 | Inavolisib | — uncovered |
| COMPLEMENT | 0.403 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.380 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.374 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.373 | Inavolisib | — uncovered |